scholarly journals The Side Effect of Haloperidol in Schizophrenic Patients: Analysis of Red Blood Cell Distribution Width (RDW) and Mean Platelet Volume (MPV) Values

2019 ◽  
Vol 11 (2) ◽  
pp. 55
Author(s):  
Andi Jayalangkara Tanra ◽  
Hawaidah Hawaidah ◽  
Yazzit Mahri ◽  
Saidah Syamsuddin ◽  
Andi Nilawati Usman ◽  
...  
Keyword(s):  
Side Effect ◽  
First Episode ◽  
Distribution Width ◽  
Before And After ◽  
Icd 10 ◽  
Schizophrenic Patients ◽  
Haloperidol Treatment ◽  
Analytic Design ◽  
First Episode Schizophrenia ◽  
Haloperidol Group

INTRODUCTION: Like the increase of pro-inflammatory cytokines and oxidative stress as schizophrenia pathophysiology, haloperidol also increases RDW and MPV values. Both of these values ​​have been clinicians concern because they are a risk factor for the various type of vascular disease. OBJECTIVE: This study aims to determine the side effect of haloperidol on RDW and MPV values in schizophrenic patients. METHODS: This research method uses observational analytic design with a prospective cohort approach with pre and posts analysis conducted at the Regional Special Hospital of South Sulawesi Province during May - July 2018 in 30 schizophrenic subjects. The subjects were diagnosed as first episode schizophrenia based on ICD 10, blood samples were taken, for RDW and MPV values ​​before and after haloperidol was given at the 4th and 8th weeks. RESULTS: The results showed that the mean RDW value at the 4th week was higher in 15 mg/day haloperidol group (15.8) compared to 7.5 mg/day haloperidol group (15.3) with p<0.05. Mean RDW value taken at 8th week was higher in 15 mg/day haloperidol group (16.4) compared to 7.5 mg/day haloperidol group (15.6) with p<0.001. Mean MPV value taken at 8th week was higher in 15 mg/day haloperidol group (13.3) compared to 7.5 mg/day haloperidol group (11.6) with p<0.001. CONCLUSION: This study showed an increase in the RDW value in schizophrenia subjects prior to the haloperidol administration. RDW ​​and MPV values were higher after haloperidol treatment compares to before haloperidol treatment. The increase of RDW and MPV values tend to be influenced by haloperidol dosage and administration duration.

Quetiapine in treatment of first episode schizophrenia

2017 ◽  
Vol 41 (S1) ◽  
pp. s809-s809
Author(s):  
N. Zivkovic ◽  
G. Djokic
Keyword(s):  
Statistical Difference ◽  
First Episode ◽  
Control Group ◽  
Dopamine Antagonist ◽  
Significant Statistical Difference ◽  
5Ht1a Receptors ◽  
Icd 10 ◽  
Competing Interest ◽  
First Episode Schizophrenia ◽  
Haloperidol Group

IntroductionAlthough there is no cure, schizophrenia is highly treatable disease. Successful first episode schizophrenia (FES) treatment is crucial to minimize personal, vocational and social deterioration. Quetiapine is atypical, second generation antipsychotic, serotonin-dopamine antagonist. Quetiapine is potent blocker of D2, 5HT2A and 5HT1A receptors.ObjectiveTo estimate efficacy of quetiapine in treatment of first episode schizophrenia.MethodsThis study included 70 patients with FES diagnosed by ICD-10 criteria, who are divided into haloperidol (H) 35 patients and quetiapine (Q) group 35 patients. Patients were observed for 6 months in hospital and extra hospital conditions, according to protocol which included Positive and Negative Symptom Schedule Scale (PANSS) and the number of withdrawals attributed to adverse event (AE). Control group was treated with haloperidol 5–20 mg/24 h and experimental group was treated with quetiapine 400–800 mg/24 h.ResultsAverage pretrial PANSS score was 110.1 in quetiapine and 108.5 in haloperidol group. Average PANSS score after 180 days was 50.6 in Q and 60.4 in H group. There is no statistical difference in pretrial scores between groups for PANSS score (P = 0.647). There is significant statistical difference in PANSS score reduction after 180 days in both groups (P < 0.001). There is significant statistical difference in PANSS score reduction between Q and H group after 180 days (P < 0.001). Overall, 8.6% AEs occurred in Q, and 25.8% in H group.ConclusionQuetiapine has shown better efficacy in treatment of FES comparing to haloperidol, with statistically significant lower adverse effects rate.Disclosure of interestThe authors have not supplied their declaration of competing interest.

The Scottish First Episode Schizophrenia Study

1992 ◽  
Vol 161 (4) ◽  
pp. 496-500 ◽  
Author(s):  
Robin G. McCreadie ◽  
David H. Wiles ◽  
Martin G. Livingston ◽  
James A. G. Watt ◽  
J. G. Greene ◽  
...  
Keyword(s):  
Psychological Distress ◽  
Drug Therapy ◽  
Psychological Stress ◽  
Antipsychotic Drug ◽  
First Episode ◽  
Poor Outcome ◽  
Schizophrenic Patients ◽  
First Episode Schizophrenia ◽  
First Admission

Forty-four schizophrenic patients were followed up for five years after their first admission to hospital for a first episode of illness. Thirteen (30%) of 43 patients had not relapsed; 28 of the 30 patients who did relapse did so within the first 42 months. The relapses occurred despite antipsychotic drug therapy. Also, 24% of patients had at least one course of ECT. Only 19% of the patients at five years were in open employment; unemployment was strongly associated with relapse. Eighteen per cent had neither relapses nor schizophrenic symptoms at follow-up. Poor outcome at five years was associated with greater psychological distress among relatives at first admission. At five years 43% of relatives continued to show case level psychological stress.

scholarly journals Neurocognition and social cognition in remitted first-episode schizophrenia: correlation with VEGF serum levels

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Yaqin Zhao ◽  
Wenhuan Xiao ◽  
Kuanyu Chen ◽  
Qiongqiong Zhan ◽  
Fei Ye ◽  
...  
Keyword(s):  
Social Cognition ◽  
Digit Span ◽  
Verbal Learning ◽  
Serum Levels ◽  
First Episode ◽  
Schizophrenic Patients ◽  
Trail Making ◽  
Learning Test ◽  
First Episode Schizophrenia ◽  
Endothelial Growth Factor

Abstract Background Accumulating evidence suggests that serum vascular endothelial growth factor (VEGF) in many neurobiological processes potentially contributes to the pathophysiology of psychiatric disorders, particularly cognitive decline. The purpose of this study was to explore the differences in neurocognition, social cognition and VEGF among remitted first-episode schizophrenic patients, non-remitters and normal control subjects. Moreover, we investigated the association between serum VEGF levels and cognitive functions. Method 65 remission (RS) and 45 nonremission patients (NRS) after first-episode schizophrenia, as well as 58 healthy controls (HC) were enrolled in this study. Social cognition was assessed using the Chinese Facial Emotion Test (CFET); neurocognition was measured with a test battery consisting of Hopkins Verbal Learning Test-Revised, Verbal Fluency Test, Trail Making Tests, Digit Span Tests (DST) and Stroop Tests. Blood samples were collected for VEGF measurements. Data was analyzed with SPSS 22.0 (Chicago, IL, USA). Results On nearly all neurocognitive tests (except for DST), RS performed significantly worse than HC but better than NRS (P < 0.05). NRS, but not RS, exhibited markedly poorer social cognition than HC (except for Happiness and Surprise subscales of the CFET) (P < 0.05). VEGF levels showed a gradient change among three groups (HC > RS > NRS). Conclusion Compared to HC, RS demonstrated poorer neurocognitive but intact social cognition functioning. These results indicate that VEGF levels decreased gradually with the severity of cognitive impairment in schizophrenia. VEGF may be involved in the pathological mechanism of cognitive performance in RS.

scholarly journals Cingulate Abnormalities Associated with PANSS Negative Scores in First Episode Schizophrenia

2000 ◽  
Vol 12 (1-2) ◽  
pp. 93-101 ◽  
Author(s):  
Liz Ashton ◽  
Anna Barnes ◽  
Martin Livingston ◽  
David Wyper ◽  
The Scottish Schizophrenia Research Group
Keyword(s):  
Negative Symptoms ◽  
Statistical Parametric Mapping ◽  
Biological Marker ◽  
Anterior Cingulate ◽  
First Episode ◽  
Cingulate Gyrus ◽  
Regional Cerebral Blood ◽  
Schizophrenic Patients ◽  
Drug Naïve ◽  
First Episode Schizophrenia

There is evidence for the involvement of the cingulate gyrus in schizophrenia. We present details of a Statistical Parametric Mapping (SPM) analysis of SPECT data from the largest study (N= 39) of drug naive schizophrenic patients. The main findings are that there is decreased perfusion in the anterior cingulate during verbal fluency when patients are compared to controls (matched individually by age, gender and father’s social class as determined by occupation) and also that PANSS negative scores correlate negatively with regional cerebral blood flow in the cingulate gyrus (Pearson’s Correlation coefficient ofr= − 0.49 and significancep< 0.005). This suggests that measurement of change of perfusion in this region could be a useful biological marker in assessing the effect of neuroleptics on negative symptoms.

The Scottish First Episode Schizophrenia Study V. One-year Follow-up

1988 ◽  
Vol 152 (4) ◽  
pp. 470-476 ◽  
Author(s):  
Robin G. McCreadie ◽  
David H. Wiles ◽  
Stewart M. Grant ◽  
John W. Moore ◽  
George T. Crocket ◽  
...  
Keyword(s):  
Block Design ◽  
Community Sample ◽  
First Episode ◽  
Psychometric Assessment ◽  
Schizophrenic Patients ◽  
One Year ◽  
First Episode Schizophrenia ◽  
Flupenthixol Decanoate ◽  
First Admission

Of 49 schizophrenic patients followed up 12 months after their first admission to hospital, only about 45% had experienced no relapse and had no schizophrenic symptoms; a poorer outcome was more often found in Feighner positive than Feighner negative schizophrenic patients. The patients' overall level of unemployment had more than doubled to 51%. In patients whose acute episodes responded to treatment, pimozide taken once weekly as maintenance therapy was as effective as intramuscular flupenthixol decanoate, but tardive dyskinesia appeared in two patients receiving weekly pimozide; the repeat psychometric assessment at 12 months found modest improvements, i.e. no evidence of intellectual decline, in Matrices, Block Design, and Digit Copying tests. Forty per cent of relatives still showed significant psychological distress, which correlated with patients' schizophrenic symptoms, and the relatives' social functioning remained poorer than that of a normal community sample.

scholarly journals A Comparison of Thioredoxin 1 Gene Expression in Schizophrenia Patients before and after Treatment with Risperidone

2021 ◽  
Vol 15 (5) ◽  
pp. 1551-1563
Author(s):  
E. Azizi ◽  
M. Hosseinzadeh ◽  
P. Vahdatian ◽  
A. Adibi ◽  
A. Azizifar ◽  
...  
Keyword(s):  
Gene Expression ◽  
Rna Extraction ◽  
Serum Levels ◽  
Key Words Schizophrenia ◽  
First Episode ◽  
Control Group ◽  
Blood Leukocytes ◽  
Before And After ◽  
Schizophrenic Patients ◽  
Dsm Iv

Background: Schizophrenia is a mental disorder characterized by distortions in thinking, perception, emotions, language, self-sense, and behavior. Recent research suggests that Reactive Oxygen Species (ROS) are involved in the pathophysiology of schizophrenia. Studies have also shown the increased plasma and serum levels of the Trx1 molecule in schizophrenia patients. In the present study, the researchers compared the expression levels of Trx1 mRNA in peripheral blood leukocytes of Iranian schizophrenia patients compared to healthy controls. Methods: First-episode patients (n=35) who met DSM-IV criteria for schizophrenia were recruited from patients referred to psychiatrists in the city of Ilam and Farabi Hospital in Kermanshah. Healthy people were also selected by recruiting people who, according to a psychiatrist, did not have any mental illness. Diagnoses were made for each patient by two independent experienced psychiatrists and confirmed by the Structured Clinical Interview for DSM-IV (SCID). Patients were treated with risperidone for three months and then compared with thirty- five healthy volunteers. Patients were sampled before and after treatment and then by RNA Extraction and DNA synthesis, Trx1 gene expression was performed by real-time PCR method. Results: Comparison of Trx1 gene expression in PBMCs of schizophrenic patients before and after treatment with the control group showed that the expression of Trx1 gene of the “before” treatment group was significantly increased compared with that of the control group (P= 0.0007). Also, Trx1 gene expression in PBMCs of “before” and “after “groups showed that Trx1 gene expression of “after” group was significantly decreased compared to the “before” group (P= 0.014). These results showed that the mean of positive, negative, and general psychopathology was reduced significantly in schizophrenic patients before and after treatment in all three cases (P <0.001). Conclusion: the expression of TRX in PBMCs of schizophrenic patients decreased after risperidone treatment. This reduction of expression was statistically significant and indicates the possible effect of risperidone on the expression of the TRX gene in PBMCs of these patients and decreased gene expression is associated with reduced symptoms. Confirmation of the achievement of this study requires further research. Key words: Schizophrenia, Thioredoxin, Risperidone

scholarly journals An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia

2009 ◽  
Vol 172 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Sarah K. Keedy ◽  
Cherise Rosen ◽  
Tin Khine ◽  
Rajaprabhakaran Rajarethinam ◽  
Philip G. Janicak ◽  
...  
Keyword(s):  
Visual Attention ◽  
First Episode ◽  
Antipsychotic Treatment ◽  
Sensorimotor Function ◽  
Fmri Study ◽  
Before And After ◽  
First Episode Schizophrenia
Sign in / Sign up

Export Citation Format

Share Document